MVM has been investing in high growth healthcare businesses since 1997. We have a broad, global, investment remit including medical technology, pharmaceuticals, biotechnology, diagnostics, life science tools, and digital health, supported by our investment teams in Boston and London.
HLS RECEIVES HEALTH CANADA LICENSE FOR CSAN PRONTO
HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™
Read moreVALNEVA'S PH II LYME STUDIES COMPLETE RECRUITMENT
Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15
Read moreCHEETAH MEDICAL ACQUIRED
Baxter International Inc, a leading global medical products company, has entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies
Read moreZIPLINE ANNOUNCES POSITIVE CLINICAL STUDY RESULTS
ZipLine Medical, Inc. announces publication of positive results from two significant clinical studies demonstrating that use of Zip® Surgical Skin Closure leads to better clinical outcomes and healthcare cost savings than do surgical staples
Read moreVALNEVA REPORTS H1 2019 MAJOR CORPORATE PROGRESS
Valneva has reported H1 2019 results marked by strong operational performance and major corporate progress
Read moreVALNEVA'S LYME DISEASE CANDIDATE - 2ND PH II STUDY
Valneva has announced the initiation of the second study of Phase II clinical development for its leading, unique Lyme disease candidate VLA15
Read moreMVM INVESTS IN HLS THERAPEUTICS
MVM invests in HLS Therapeutics Inc which acquires and commercializes branded pharmaceuticals in central nervous system and cardiovascular therapeutic areas for the North American market
Read moreNEW VALIDATION DATA FOR THE BREAST CANCER INDEX
Biotheranostics, Inc. has announced new pivotal data on the Breast Cancer Index (BCI) that further validates its ability to accurately predict which women with early-stage, hormone receptor positive (HR+) breast cancer will benefit from extended endocrine therapy
Read morePOSITIVE RESULTS FOR VALNEVA CHIKUNGUNYA VACCINE
Valneva reports further positive results for Its Chikungunya vaccine candidate
Read moreZIPLINE MEDICAL - 2019 RED HERRING TOP 100 WINNER
ZipLine selected as a winner of the Red Herring Top 100 North America award, which recognizes the continent's most exciting and innovative private technology companies
Read moreMVM ANNOUNCES PARTIAL SALE OF ITS AMBIO HOLDING
MVM Partners LLP has partially divested its stake in Ambio Holdings, Inc., a global leader in peptide manufacturing and development to The Carlyle Group
Read moreALLIANCE RECEIVES POSITIVE OPINION FOR DICLECTIN
Alliance Pharma announces that the MHRA and the CHM have advised that the Marketing Authorisation Application for Diclectin® is now considered approvable
Read moreALEXION TO ACQUIRE WILSON THERAPEUTICS
Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals
Read more